E. Raschi; E. Poluzzi; A. Koci; F. De Ponti, Reporting frequency of QT-interval abnormalities in the FDA Adverse Event Reporting System (FDA_AERS)., in: Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, 26-29 June 2011, Budapest, Hungary, «BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY», 2011, 109, pp. 56 - 184 (atti di: 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, June 26-29) [Abstract]
Raschi E.; Boriani G.; De Ponti F., Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling, «CURRENT DRUG TARGETS», 2011, 12, pp. 263 - 286 [Scientific article]
Raschi, E; Vasina, V; Ursino, M G; Boriani, G; Martoni, A; De Ponti, F, Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy., «PHARMACOLOGY & THERAPEUTICS», 2010, 125, pp. 196 - 218 [Scientific article]
E. Poluzzi; E. Raschi; D. Motola; U. Moretti; F. De Ponti, Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System, «DRUG SAFETY», 2010, 33, pp. 303 - 314 [Scientific article]
Piccinni C.; Motola D.; Biagi C.; Raschi E.; Marra A.; Marchesini G.; Poluzzi E., Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS, in: Riassunti, ROMA, ISTITUTO SUPERIORE DI SANITÀ, «ISTISAN CONGRESSI», 2010, 10/C7, pp. 26 - 27 (atti di: XIX Seminario Nazionale. La valutazione dell'uso e della sicurezza dei farmaci:esperienze in Italia, Istituto Superiore di Sanità, Roma, 13 dicembre 2010) [Abstract]
Boriani G; Diemberger I; Valzania C; Biffi M; Martignani C; Raschi E; Mantovani V; Ziacchi M; Bertini M; De Ponti F; Branzi A., Role of drugs and devices in patients at risk of sudden cardiac death., «FUNDAMENTAL & CLINICAL PHARMACOLOGY», 2010, 24, pp. 575 - 594 [Scientific article]
E. Raschi; E. Poluzzi; U. Moretti; F. De Ponti, TdP liability of fluoroquinolones: integrated approach based on the FDA spontaneous reports and literature data., in: Supplement: Abstracts from the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Rhode Island Convention Center, Providence, Rhode Island, USA. August 16–19, 2009, «PHARMACOEPIDEMIOLOGY AND DRUG SAFETY», 2010, 19, pp. S1 - S347 (atti di: 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, August 17-22) [Abstract]
E. Poluzzi; E. Raschi; D. Motola; U. Moretti; F. De Ponti, Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System., «BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY», 2009, 105, pp. 31 - 31 [Scientific article]
Poluzzi E; Raschi E; Moretti U; De Ponti F., Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)., «PHARMACOEPIDEMIOLOGY AND DRUG SAFETY», 2009, 18, pp. 512 - 518 [Scientific article]
Raschi E; Poluzzi E; Zuliani C; Muller A; Goossens H; De Ponti F., Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period., «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2009, 67, pp. 88 - 98 [Scientific article]
Raschi E.; Ceccarini L.; De Ponti F.; Recanatini M., hERG-related drug toxicity and models for predicting hERG liability and QT prolongation, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2009, 5, pp. 1005 - 1021 [Scientific article]
Ursino M.G.; Vasina V.; Raschi E.; Crema F.; De Ponti F., The beta3-adrenoceptor as a therapeutic target: current perspectives., «PHARMACOLOGICAL RESEARCH», 2009, 59, pp. 221 - 234 [Scientific article]
E. Poluzzi; E. Raschi; C. Zuliani; A. Muller; H. Goossens; F. De Ponti, Exposure to antibacterials with QT-liability in 15 European countries: trends over a 7-year period., in: Supplement: Abstracts of the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Copenhagen, Denmark, August 17–20, 2008., «PHARMACOEPIDEMIOLOGY AND DRUG SAFETY», 2008, 17, pp. S1 - S294. (atti di: 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Copenaghen, August 17-20) [Abstract]
Raschi E; Vasina V; Poluzzi E; De Ponti F., The hERG K+ channel: target and antitarget strategies in drug development., «PHARMACOLOGICAL RESEARCH», 2008, 57, pp. 181 - 195 [Scientific article]
Poluzzi E.; Piccinni C.; Raschi E.; Mazzolani M.; Angelini C.; D’Alessandro R.; Martinelli P.; Quatrale R.; Calzetti S.; Montanaro N., Prescrizione di Entacapone nella Regione Emilia-Romagna, in: Riassunti, ROMA, ISTITUTO SUPERIORE DI SANITÀ, «ISTISAN CONGRESSI», 2006, 06/c10, pp. 82 - 82 (atti di: XV Seminario Nazionale. La valutazione dell’uso e della sicurezza dei farmaci: esperienze in Italia, Istituto Superiore di Sanità, Roma, 11-12 dicembre 2006) [Abstract]
